CLINICAL_TRIALS
trial_result
· 2025-09-10
Clinical Trial Update: Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia [Phase 2]
Summary
Phase 2 study evaluating the efficacy, safety, and pharmacokinetics of CPL500036 in schizophrenia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celon Pharma SA | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED